Long-term gonadotrophin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms.
The introduction of steroid 'add-back' regimens draws on the recognition that several clinical entities targeted for treatment with gonadotrophin-releasing hormone agonist (GnRHa) are not '6-month diseases'. Included under this heading are individuals suffering from symptomatic endometriosis (not desires of pregnancy), uterine fibroids (ineligible or disinterested in definitive surgical therapy), ovarian hyperandrogenism, premenstrual syndrome, menopausal transition, or dysfunctional uterine bleeding. A 6-month course of therapy with a GnRHa does not adversely affect lipoprotein economy and therefore presumably the corresponding cardiovascular risk. A 6-month course of GnRHa therapy appears to be associated with a substantial decrease (of up to 8.2%) in lumbar bone density, a phenomenon which may not be entirely reversible 6 months after discontinuation of therapy. In principle, steroid 'add-back' therapy should diminish some or all of the side-effects associated with GnRHa therapy, may provide a medical treatment option for patients representing a high surgical risk, and may delay surgical intervention if desired. On the other hand, a steroid 'add-back' therapy may delay tissue diagnosis, be associated with a substantial cost as well as with the need for parenteral route of administration. Norethindrone-only (but not medroxyprogesterone acetate-only) 'add-back' regimens have proved promising in the context of endometriosis. Non-concurrent oestrogen/progestin 'add-back' regimens proved promising in the context of uterine fibroids. Substantial additional studies would have to be carried out to validate the utility of steroid 'add-back' regimens. Special emphasis will have to be placed on the evaluation of long-term utility with an eye towards assessing clinical efficacy, impact on lipoprotein economy, impact on bone density, impact on urogenital tissues, and impact on the hot flush. The concurrent or non-concurrent use of non-steroid 'add-back' regimens will also most likely constitute a major component of future studies.
Adashi
E Y
EY
Department of Obstetrics and Gynecology, University of Maryland School of Medicine, Baltimore 21201.
D015519:Bone Density / Q000187:drug effects; D001943:Breast Neoplasms / Q000517:prevention & control; D002319:Cardiovascular System / Q000187:drug effects; D002979:Climacteric / Q000187:drug effects; D004412:Dysmenorrhea / Q000188:drug therapy; D004715:Endometriosis / Q000188:drug therapy; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D017588:Hyperandrogenism / Q000188:drug therapy; D007889:Leiomyoma / Q000188:drug therapy; D010024:Osteoporosis / Q000139:chemically induced; D011293:Premenstrual Syndrome / Q000188:drug therapy; D045167:Progesterone Congeners / Q000627:therapeutic use; D012307:Risk Factors; D013256:Steroids / Q000627:therapeutic use
D045167:Progesterone Congeners; D013256:Steroids; D007987:Gonadotropin-Releasing Hormone